Malignant Muscle Neoplasm — Trials

Malignant Muscle Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 106
Recruiting: 58
Ph III recruiting: 6
Growth YoY: −35%
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (42)

clinicaltrialsPublishedShowing 51–100 of 325 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06088290	Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo)	active not recruiting	Phase 3	469	PharmaMarINDUSTRY	12	Jun 18, 2026	clinicaltrials
NCT06571734	XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma	recruiting	Phase 2	73	Northwestern UniversityOTHER	1	Jun 18, 2026